During the exhibition, our core team engaged in extensive discussions with global peers, clinical researchers, biotech companies, and industry regulators in the CAR-T and advanced cell therapy sectors. Our interactions focused on three key business areas: anti-idiotype (Anti-ID) antibodies, VHH nanobody development for in vivo CAR-T applications, and customized ADA & CAR-T monitoring assay solutions.
Given the rapid pace of technological advancement in the CAR-T field, our team collected over 102 cutting-edge research posters for subsequent technical review and product optimization. Through proactive pre-event preparation and active on-site engagement, CytoArt established multiple potential collaborations with both new and long-term partners from China and the United States. These interactions laid a strong foundation for future co-development projects in customized antibodies and monitoring reagents.